Pharmacotherapy in Neonatal and Pediatric Extracorporeal Membrane Oxygenation (ECMO)

E.D. Wildschut, Maurice Ahsman, Robert jan Houmes, P Pokorna, Saskia de Wildt, RAA Mathot, Dick Tibboel

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)


ECMO support is an established life saving therapy for potentially reversible respiratory and/or cardiac failure. Improvement of outcome depends on effective treatment of the primary diagnosis and complications. Adequate drug therapy is important in reaching these goals. Pharmacokinetic and pharmacodynamic data in neonates and older children on ECMO are sparse. Most studies show altered volume of distribution and clearance for the drugs studied. This article gives an overview of the available PK and PD studies in neonates and children on ECMO, suggests possible mechanisms of altered PK and PD and identifies areas of interest for further research.
Original languageUndefined/Unknown
Pages (from-to)767-777
Number of pages11
JournalCurrent Drug Metabolism
Issue number6
Publication statusPublished - 2012

Research programs

  • EMC MGC-02-53-01-A

Cite this